GBM-5003 v1

Fan, Z.-P., Cao, Y., Huang, C.-Y., & Li, Y. (2020). Pricing strategies of domestic and imported electric vehicle manufacturers and the design of government subsidy and tariff policies. Transportation Research Part E, 143.
This paper investigates the optimal pricing strategies of domestic/imported electric vehicle manufacturers and the government’s optimal decisions by developing the game-theoretic models. The results show that the technology spillover caused by introducing IEVs into domestic markets can affect electric vehicle manufacturers' profits and the government’s decisions on subsidies and tariffs.

Gherasim, D., & Gherasim, A. (2019). Strategies regarding prices within the international marketing. Economy Transdisciplinarity Cognition, 22(2), 62.
Companies doing international business can adopt different types of marketing strategies on prices. Depending on the lifecycle of the company's products, there are strategies for new products (high price strategy, penetration strategy, price strategy stratification strategy, standard price strategy) and strategies for existing products (a strategy with different price levels, product price strategy, price strategy of global products, pricing strategy based on incentives and bonuses; price strategy for optional products, differentiated pricing strategy).

He, Q., & Zheng, X. (2020). Price discrimination across different ticket distribution channels: Evidence from the US-China flight market. China Economic Review, 61.
In the U.S.-China international flight market, airlines sell tickets in two different distribution channels at vastly different prices. This article provides a rare opportunity to examine how airlines practice price discrimination across different ticket distribution channels. This study finds that price discrimination across different ticket distribution channels is not influenced by market competition, but increases with demand.

Hughes, R. C. (2020). Pricing medicine fairly. Philosophy of Management, 19(4), 369.
To the extent possible, pharmaceutical companies must price drugs so that those who genuinely need them can get them without financial ruin. This requirement is an ethical side constraint, like the moral prohibitions on deception and theft, that takes precedence over a business’s interest in maximizing profit. Either price regulation or subsidy could fulfill the government’s obligation to protect patients from being objectionably vulnerable to private companies' pricing decisions.